Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRT100 in Acute Spinal Cord Injury
NCT05739734Phase 1Recruiting
- Sponsor
- Cristália
- Start
- Sep 2026
- Primary completion
- Dec 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CRIS100 in thoracic spinal cord injury (TSCI), sponsored by Cristália. Primary endpoint: Safety at 6 months. Started Sep 2026; status: recruiting.
02
Drugs
CRIS100
03
Conditions
thoracic spinal cord injury (TSCI)
Beyond the preview
Go deeper on NCT05739734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05739734.